Clinical trials: Probes
Healthy Volunteers
Drug Interaction Study of CT1812 in Healthy Volunteers
This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and…
- Trial name
- NCT03716427
- Testing
- CT1812, tolbutamide, dextromethorphan
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Healthy
Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects
The purpose of this study is to evaluate the effect of single doses of midazolam on the plasma concentration of a single dose of moxidectin in healthy young adult subjects, and to assess the safety of co-administration of…
- Trial name
- NCT00856362
- Testing
- Moxidectin, Midazolam
- Where
- Germany
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects
- Trial name
- NCT03845907
- Testing
- Gen 1B, Gen 1
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Seno Medical Instruments Inc.
Healthy
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants
This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.
- Trial name
- NCT07259330
- Testing
- Nirogacestat, Nirogacestat and Cocktail of CYP Specific Probe Substrates
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Age-related Skin Changes
Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Imaging Modalities in Chinese Subjects
Evaluation of age-related skin changes using clinical probe measurements and imaging modalities in Chinese subjects.
- Trial name
- NCT04655300
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Allergan
Chlamydia Infections, Gonorrhea
Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays
The objective of this study is to obtain female first-catch urine, vaginal, cervical and endocervical swabs for testing with multiple APTIMA Assays on the Gen-Probe PANTHER® and TIGRIS® Systems.
- Conditions
- Chlamydia Infections, Gonorrhea, Trichomonas Infections
- Trial name
- NCT01728103
- Testing
- APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays
- Where
- 14 sites in United States
- Volunteers
- 1,336 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Healthy Volunteers
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin
- Trial name
- NCT07567781
- Testing
- ABBV-722, Midazolam, Metformin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Subjects
A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
This study is to determine the effect of single and multiple oral doses of mifepristone on the pharmacokinetics of a single oral dose of fluvastatin administered to healthy volunteers.
- Trial name
- NCT00752843
- Testing
- mifepristone + fluvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Drug Drug Interaction (DDI)
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together.
- Trial name
- NCT06632990
- Testing
- BMS-984923, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Allyx Therapeutics
Cardiovascular Disease
A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects
In clinical practice, AZD5718 will be co-administered with CYP3A substrates. Therefore, it is important to determine the impact of AZD5718 on the pharmacokinetics (PK) of CYP3A4 substrates.
- Trial name
- NCT04492709
- Testing
- Midazolam, AZD5718
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers
The objective of this trial was to quantify the effect of oral single-dose (480 mg) and steady-state BI 201335 NA (240 mg BID) on intestinal and hepatic cytochrome P450 (CYP) and P-glycoprotein (P-gp) probe drugs as a means of…
- Trial name
- NCT02182336
- Testing
- BI 201335 NA, Caffeine, Warfarin sodium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
This is a single-centre, open-label, fixed-sequence, 2-period study in healthy participants. The total study duration for each participant will be up to approximately 56 days, including a 28-day screening period, a 19-day…
- Trial name
- NCT07840612
- Testing
- Mirdametinib, Probenecid
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Influenza in Humans
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy…
- Trial name
- NCT02888327
- Testing
- AL-794, Oseltamivir, Digoxin
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Healthy
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
- Trial name
- NCT05694533
- Testing
- INDV-2000, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Healthy
A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects
The main purpose of this study is to determine the potential inhibitory/inducing effects of JNJ-54175446 after single and repeated dosing on the single-dose pharmacokinetics (PK) of a cocktail, containing selective probes of…
- Trial name
- NCT03058419
- Testing
- JNJ-54175446 150 mg, JNJ-54175446 600 mg, Midazolam 2 mg
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis B
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
This is a drug-drug interaction study conducted in healthy volunteers to evaluate the effect of HRS5091 on CYP3A4, CYP2C9, CYP2C19, P-gp, BCRP and OATP1B1, using midazolam, s-warfarin, omeprazole, digoxin and rosuvastatin as…
- Trial name
- NCT05273775
- Testing
- HRS5091 Tablets, Midazolam Maleate Tablets, Warfarin Sodium Tablets
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are…
- Trial name
- NCT05981365
- Testing
- Voxelotor, Bupropion, Repaglinide
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Drug-drug interaction study in healthy men and women not of childbearing potential. Assess the effect of BMS-986195 on the pharmacokinetics of methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and…
- Trial name
- NCT03131973
- Testing
- BMS-986195, Methotrexate, Leucovorin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Evaluate the effect of darolutamide on the pharmacokinetics of a probe CYP3A4 substrate and Pgp substrate
- Trial name
- NCT03237416
- Testing
- Dabigatran etexilate, Midazolam, BAY1841788 (darolutamide)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer